ALRN — Aileron Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $84.86m
- $158.96m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 30 | 20.5 | 26.3 | 27.6 | 16.3 |
Operating Profit | -30 | -20.5 | -26.3 | -27.6 | -16.3 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -29.4 | -21.2 | -26.2 | -27.3 | -15.7 |
Net Income After Taxes | -29.4 | -21.2 | -26.2 | -27.3 | -15.7 |
Net Income Before Extraordinary Items | |||||
Net Income | -29.4 | -21.2 | -26.2 | -27.3 | -15.7 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -29.4 | -21.2 | -26.2 | -27.3 | -15.7 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -23.9 | -11.7 | -5.98 | -6.02 | -3.23 |